Investors & Media

Investors & Media

Corporate Profile

Aileron Therapeutics is focused on transforming the experience of chemotherapy for cancer patients, enabling them to fight cancer without the fear or burden of chemotherapy-induced side effects. We are advancing ALRN-6924, our first-in-class dual MDM2/MDMX inhibitor currently in clinical development, to provide a single medicine to protect multiple healthy cell types throughout the body from chemotherapy while ensuring chemotherapy continues to destroy cancer cells.

More >>


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Company continues to develop ALRN-6924 as novel chemoprotective medicine to protect patients from chemotherapy-induced toxicities and side effects -- Positive interim dose optimization data from proof...
WATERTOWN, Mass. , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two ...
Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported posit...

Investor Contacts

Rick Wanstall

Chief Financial Officer and Treasurer

LifeSci Advisors, LLC.

Hans C. Vitzthum